Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Paieon Inc.
ClinicalTrials.gov Identifier:
NCT00973921
First received: September 6, 2009
Last updated: March 6, 2014
Last verified: March 2014

September 6, 2009
March 6, 2014
September 2009
March 2010   (final data collection date for primary outcome measure)
  • The Accuracy (Percent of Correct Decisions) of Post-dilatation Decisions Based on the Stent Optimizer (SO) Software, With IVUS as Gold Standard. [ Time Frame: On the procedure day ] [ Designated as safety issue: No ]
    IVUS was used as a gold standard to decide if a stent required post dilatation or not. Independently and blindly, The SO software was used to determine the same decisions. The accuracy of SO was determined as the percentage of correct decisions compared to the gold standard.
  • The Accuracy (Percent of Correct Decisions) of Post-dilatation Decisions Based on QCA Analysis, With IVUS as Gold Standard. [ Time Frame: On procedure day ] [ Designated as safety issue: No ]
    IVUS was used as a gold standard to decide if a stent required post dilatation or not. Independently and blindly, QCA analysis was used to determine the same decisions. The accuracy of SO was determined as the percentage of correct decisions compared to the gold standard.
The primary objective of this study is to determine the diagnostic efficiency and accuracy of using the StentOptimizer. The ability of StentOptimizer to influence post deployment treatment strategy will be assessed and compared to the IVUS system [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00973921 on ClinicalTrials.gov Archive Site
  • Correlation of Stent Diameter Measurements Between the StentOptimizer and IVUS . [ Time Frame: On day of procedure ] [ Designated as safety issue: No ]
    The mean difference between stent diameter measurements at the narrowest point (Minimum Stent Diameter) by SO and by IVUS.
  • Correlation of Stent Diameter Measurements Between the QCA and IVUS . [ Time Frame: On day of procedure ] [ Designated as safety issue: No ]
    The mean difference between stent diameter measurements at the narrowest point (Minimum Stent Diameter) by QCA and by IVUS
In addition, the correlation of diameter measurements between the StentOptimizer, IVUS and 2D QCA will be assessed. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Comparison of StentOptimizer With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography
Comparison of StentOptimizer - an Angiography-based Post Deployment Stent Analysis Application With IntraVenous Ultrasound and 2D Quantitative Coronary Angiography for Post Deployment Stent Analysis

The primary objective of this study is to determine the diagnostic efficiency and accuracy of using the StentOptimizer. The ability of StentOptimizer to influence post deployment treatment strategy will be assessed and compared to the IVUS system. In addition, the correlation of diameter measurements between the StentOptimizer, IVUS and 2D QCA will be assessed. The StentOptimizer software, IVUS and 2D QCA were all part of the clinical procedure outside the study. The analysis of post deployment treatment decisions and diameter measurements using those modalities retrospectively make this an observational study.

Stent under-expansion is defined as the minimum stent area by itself or compared with a predefined reference. It plays a role in the pathogenesis of adverse events following stent deployment. Stent under-expansion has been a consistent finding in IVUS reports of acute or subacute BMS or DES thrombosis.

Post intervention imaging can determine whether there is adequate stent expansion. Currently the only available tool for evaluation of properness of stent deployment is intravascular ultrasound (IVUS). IVUS procedure is invasive, labor intensified, associated with radiation and contrast media use, and is not free of complications. In many medical centers, IVUS is not used routinely because of lack of knowledge and expertise in reading it, and it's relatively high price.

The StentOptimizer is an angiography based software tool aimed to enhance visualization of deployed stents and to provide the physician with quantitative data regarding stent dimensions. The StentOptimizer is part of an image acquisition and processing software system (IC-Pro), designed as an add-on to conventional X-ray angiography systems.

An enhanced stent image is produced using the radiopaque markers of the delivery balloon from several frames (minimum 20). The result is a still image of the stent with enhanced edges and the region of interest around it

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Consecutive patients that underwent IVUS guided stent implantation in the institution.

Coronary Artery Disease
Not Provided
Stent deployment evaluation
The study group consisted of patients that underwent IVUS guided stent implantation. Stent deployment evaluation was done with the experimental StentOptimizer as well as IVUS and QCA.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
March 2010
March 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Percutaneous coronary intervention indicated clinically.
  2. IVUS used as part of the standard procedure.
  3. Subject must be >=40 yrs.
  4. Subject must provide written informed consent.

Exclusion Criteria:

  1. Low image quality as determined by the investigator.
  2. Subject is pregnant or nursing.
  3. Acute ST segment elevation myocardial infarction (STEMI) that has not been stabilized.
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00973921
Paieon-Columbia-SO
No
Paieon Inc.
Paieon Inc.
Not Provided
Principal Investigator: Giora Weisz, MD Columbia University
Paieon Inc.
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP